BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3132043)

  • 1. The varying effects of progestins on lipid levels and cardiovascular disease.
    La Rosa JC
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1621-9. PubMed ID: 3132043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins.
    Bergink EW; Kloosterboer HJ; Lund L; Nummi S
    Contraception; 1984 Jul; 30(1):61-72. PubMed ID: 6236951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
    Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS
    Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives, lipoproteins, and atherosclerosis.
    Adams MR; Clarkson TB; Shively CA; Parks JS; Kaplan JR
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1388-93. PubMed ID: 2220963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
    Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
    Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
    Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
    Oyelola OO
    Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism.
    Kloosterboer HJ; van Wayjen RG; van den Ende A
    Contraception; 1986 Aug; 34(2):135-44. PubMed ID: 2946552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women.
    Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B
    Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.